Biotech, Biomaterials and Biomedical: TechConnect Briefs 2015Biotech, Biomaterials and Biomedical TechConnect Briefs 2015

Materials for Drug & Gene Delivery Chapter 1

Peptide RF482 Encapsulated Chitosan – PLGA Nanoparticles Inhibit Respiratory Syncytial Virus

S.S. Bawage, P.M. Tiwari, V.A. Dennis, S.R. Singh
Alabama State University, United States

pp. 52 - 55

Keywords: RSV, chitosan, PLGA, fusion inhibitors, nanoparticles

Worldwide, human respiratory syncytial virus (RSV) is one of the leading causes of lower respiratory tract infections in children and older adults. Currently, an anti-viral drug ribavirin and RSV neutralizing monoclonal antibody- palivizumab are the only relief options. However, efficacy, cost and adverse effects are the problems associated with them. Nanotechnology has significantly contributed in the medicine, especially, drug delivery. Nano-encapsulation of drugs provides the advantage of longer retention and controlled release. RSV infects the host cells by F protein mediated cell membrane fusion. Chemical or protein fusion inhibitors that block this vital step of RSV infection are currently explored. In this study, we synthesized the biodegradable nanoparticles by double emulsion method, firstly we encapsulated RSV F protein derived RF482 peptide (a fusion inhibitor) with poly [lactic acid-glycolic acid] (PLGA) and then by chitosan. Our study showed that, the mucoadhesive chitosan-PLGA nanoparticles (without RF482 peptide) contribute in RSV inhibition. However, the RF482 peptide encapsulated chitosan-PLGA nanoparticles treatment showed higher RSV inhibition than the unloaded nanoparticles.